Last $3.40 USD
Change Today +0.04 / 1.19%
Volume 220.5K
RIGL On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

rigel pharmaceuticals inc (RIGL) Snapshot

Open
$3.33
Previous Close
$3.36
Day High
$3.44
Day Low
$3.32
52 Week High
03/17/14 - $5.00
52 Week Low
12/18/13 - $2.31
Market Cap
297.6M
Average Volume 10 Days
434.1K
EPS TTM
$-0.96
Shares Outstanding
87.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RIGEL PHARMACEUTICALS INC (RIGL)

rigel pharmaceuticals inc (RIGL) Related Businessweek News

No Related Businessweek News Found

rigel pharmaceuticals inc (RIGL) Details

Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. Its product development programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor that intends to enter Phase III clinical trials for immune thrombocytopenic purpura and a Phase II clinical trial for immunoglobulin A nephropathy; R348, a topical janus kinase/SYK inhibitor in Phase II clinical trials for the treatment of keratoconjunctivitis sicca or chronic dry eye; R118, an adenosine monophosphate-activated protein kinase activator that intends to enter Phase I clinical trial; and two oncology product candidates in Phase I development. It also has small molecule discovery programs in muscle wasting. Rigel Pharmaceuticals, Inc. has collaboration agreement Daiichi Sankyo to pursue research related to a specific target from a class of drug targets called ligases that control cancer cell proliferation through protein degradation; and a license agreement with BerGenBio AS for the development and commercialization of an oncology program. The company was founded in 1996 and is based in South San Francisco, California.

129 Employees
Last Reported Date: 03/4/14
Founded in 1996

rigel pharmaceuticals inc (RIGL) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: $695.1K
President and Chief Operating Officer
Total Annual Compensation: $551.7K
Co-Founder, Executive Vice President, Directo...
Total Annual Compensation: $559.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $441.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2013.

rigel pharmaceuticals inc (RIGL) Key Developments

Rigel Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-25-2014 09:30 AM

Rigel Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-25-2014 09:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Rigel Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:30 PM

Rigel Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-03-2014 02:30 PM. Venue: Grand Hyatt, New York, New York, United States. Speakers: James M. Gower, Chairman, Chief Executive Officer and Member of Finance Committee.

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net loss was $22,303,000 or $0.25 per basic and diluted share against net loss was $25,574,000 or $0.29 per basic and diluted share a year ago. Loss from operations was $22,385,000 compared to $25,710,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RIGL:US $3.40 USD +0.04

RIGL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.43 USD 0.00
Array BioPharma Inc $4.07 USD +0.01
CrystalGenomics Inc 14,050 KRW -50.00
CTI BioPharma Corp $2.69 USD -0.01
Progenics Pharmaceuticals Inc $4.24 USD -0.02
View Industry Companies
 

Industry Analysis

RIGL

Industry Average

Valuation RIGL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 41.6x
Price/Book 1.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RIGEL PHARMACEUTICALS INC, please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.